scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
97 hedge funds and large institutions have $146M invested in scPharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
48% more capital invested
Capital invested by funds: $98.7M → $146M (+$47M)
10% more funds holding
Funds holding: 88 → 97 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
2.25% less ownership
Funds ownership: 74.67% → 72.42% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.64M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.56M |
| 3 |
Millennium Management
New York
|
+$1.41M |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$1.3M |
| 5 |
Morgan Stanley
New York
|
+$813K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$1.44M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.06M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$914K |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$710K |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$558K |
SCPH Hedge Fund Activity: Q2 2025 in Review
97 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2025, worth a combined $146M — up 48% from $98.7M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SCPH positions and 13 closed out — a net gain of 9 holders — while 30 added to existing stakes and 32 trimmed.
The largest buyer was UBS Group, adding an estimated $1.64M. The largest seller was J. Goldman & Co, cutting an estimated $1.44M.
- 97 institutional investors held scPharmaceuticals (SCPH) as of Q2 2025, up from 88 in Q1 2025.
- Funds reported $146M of scPharmaceuticals stock for Q2 2025, up 48% quarter-over-quarter.
- 22 funds opened new scPharmaceuticals positions in Q2 2025 and 13 closed out, a net change of +9 holders.
- The largest scPharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $1.64M added.
- The largest scPharmaceuticals seller in Q2 2025 was J. Goldman & Co, an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2025.